The management of porphyria cutanea tarda

Clinical and Experimental Dermatology

Volumn 26, Issue 3, 2001, Pages 225-232

  Sarkany, R P E ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTIMALARIAL AGENT; CHLOROQUINE; DEFEROXAMINE; ESTROGEN; HYDROXYCHLOROQUINE; UROPORPHYRINOGEN DECARBOXYLASE;

BLISTER; CHEMICAL ANALYSIS; CLINICAL FEATURE; DISEASE COURSE; DISEASE SEVERITY; ENZYME INHIBITION; FOLLOW UP; GENETIC DISORDER; HEMOCHROMATOSIS; HEPATITIS C VIRUS; HUMAN; IRON OVERLOAD; LIGHT EXPOSURE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER DISEASE; MONITORING; PATHOGENESIS; PHLEBOTOMY; PORPHYRIA CUTANEA TARDA; PORPHYRIA VARIEGATA; PRIORITY JOURNAL; RELAPSE; REVIEW; RISK FACTOR; VIRUS INFECTION;

HUMANS; LIVER DISEASES; PORPHYRIA CUTANEA TARDA; RISK FACTORS;

EID: 0035724150     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2230.2001.00825.x     Document Type: Review

References (54)

1. Porphyria cutanea tarda
2. Studien über porphyrie
3. Untersuchungen über die biologische (photodynamische) wirkung des hämatoporphyrins und anderer derivate des blut- und gallenfarbstoffs
4. Activation of the complement system in patients with porphyrias after irradiation in vivo
5. Porphyria cutanea tarda: Clinical features and laboratory findings in 40 patients
6. Microscopic and fine structural aspects of porphyrias
7. Uroporphyrinogen-decarboxylase deficiencies: Porphyria cutanea tarda and related conditions
8. Porphyria and scleroderma: A clinical and laboratory review of 12 patients
9. Contraceptive pill-induced porphyria cutanea tarda presenting with onycholysis of the finger nails
10. Hepatoerythropoietic porphyria: Relationship with familial porphyria cutanea tarda
11. Immunoreactive uroporphyrinogen decarboxylase in the liver in porphyria cutanea tarda
12. Industrially acquired porphyria
13. Uroporphyrinogen decarboxylase and protoporphyrinogen oxidase in dual porphyria
14. Rapid and accurate random urinary porphyrin quantitation
15. Alcohol intake and porphyria cutanea tarda
16. Liver involvement in porphyria
17. Iron storage, lipid peroxidation and glutathione turnover in chronic HCV-positive hepatitis
18. Interrelationships of alcohol and iron in liver disease with particular reference to the iron-binding proteins, ferritin and transferrin
19. Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda
20. Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda
21. Iron overload in porphyria cutanea tarda
22. Alcohol mediates increases in hepatic and serum nonheme iron stores in a rat model for alcohol-induced liver injury
23. Hepatitis C virus and porphyria cutanea tarda: Evidence of a strong association
24. Role of hepatitis C virus in porphyria cutanea tarda hepatopathy
25. Low prevalence of hepatitis C virus infection in porphyria cutanea tarda in Germany
26. HCV infection in porphyria cutanea tarda
27. Screening of patients with iron overload to identify haemochromatosis and porphyria cutanea tarda
28. Abnormal urinary coproporphyrin levels in patients infected by Hepatitis C virus with or without human immunodeficiency virus: A study of 177 patients
29. Adult form of chronic porphyria with cutaneous manifestations
30. Porphyria cutanea tarda: Comparison of cases precipitated by alcohol and estrogens
31. Treatment of porphyria cutanea tarda of end-stage renal disease with erythropoietin
32. Porphyria cutanea tarda and human immunodeficiency virus infection
33. Porphyrin abnormalities in acquired immunodeficiency syndrome
34. Lupus erythematosus and porphyria
35. Hepatocarcinogenicity of hexachlorobenzene in rats and the sex difference in hepatic iron status and development of porphyria
36. Hepatocellular carcinoma in porphyria cutanea tarda: Frequency and factors related to its occurrence
37. Porphyria cutanea tarda and hepatocellular carcinoma. Frequency of occurrence and related factors
38. Acquired porphyria from a liver tumor
39. Dramatic resolution of skin lesions associated with porphyria cutanea tarda after interferon-alpha therapy in a case of chronic hepatitis C
40. Chloroquine in treatment of porphyria cutanea tarda: Long-term efficacy of combined phlebotomy and high-dose chloroquine therapy
41. Plasma ferritin levels as a guide to the treatment of porphyria cutanea tarda by venesection
42. Porphyria and scleroderma: A clinical and laboratory review of 12 patients
43. A comparative study of the results of phlebotomy therapy and low-dose chloroquine treatment in porphyria cutanea tarda
44. Iron removal therapy in porphyria cutanea tarda: Phlebotomy versus slow subcutaneous desferrioxamine infusion
45. Porphyria cutanea tarda: Report of a case successfully treated with chloroquine
46. Porphyria cutanea tarda treated with chloroquine phosphate
47. Low-dose oral chloroquine in the treatment of porphyria cutanea tarda
48. Low-dose oral chloroquine in patients with porphyria cutanea tarda and low-moderate iron overload
49. Agents affecting porphyrin formation and secretion: Implications for porphyria cutanea tarda treatment
50. Hydroxychloroquine versus phlebotomy in the treatment of porphyria cutanea tarda
51. Hydroxychloroquine treament of porphyria cutanea tarda
52. The molecular basis of the action of chloroquine in porphyria cutanea tarda
53. Commentary: Iron metabolism in Hepatitis C infection